Pharmacokinetic Studies Participation Survey

Completed

Conditions studied: Relapsed Solid Tumors, Relapsed Leukemia, Relapsed Brain Tumors

In brief

Background: * A pharmacokinetic (PK) study of a new drug involves taking several blood samples over a period of time from study participants to determine how the body handles the substance. These studies provide critical information about new drugs. * Often, patients or parents of children in drug studies choose not to participate in optional PK studies that are part of the study protocol. * A better understanding of why patients or families do or do not agree to participate in PK studies may help researchers make it easier for people to participate in them. Objectives: * To learn why some people do or do not agree to participate in PK blood sampling studies. Eligibility: * Patients 18 years of age and older and parents or guardians of children who are participating in a study of a drug that includes the option of participating in PK sampling. Design: * Participants fill out a 2-page survey asking about why they did or did not participate in the study's PK sampling.

Key facts

Study ID

NCT00923468

Run by

National Cancer Institute (NCI)

People needed

25

Starts

2008-09-23

Last updated by the study team

2017-07-02

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

Where it is running

• National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.